Today: 8 February 2026
Subscribe
Browse Category

NYSE:LLY News 29 December 2025 - 6 January 2026

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly shares rose about 1.6% Tuesday after Nimbus Therapeutics announced a deal to develop an oral obesity drug with the company. Nimbus will receive $55 million upfront and could get up to $1.3 billion in total payments plus royalties. The agreement follows Novo Nordisk’s U.S. launch of its $149-a-month Wegovy pill, intensifying focus on oral weight-loss treatments.
6 January 2026
··
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly shares fell 3.6% to $1,041.51 in after-hours trading Monday after Novo Nordisk launched a pill version of its Wegovy weight-loss drug in the U.S. Novo’s shares rose 5.2% as investors reacted to new pricing and distribution details. Lilly’s stock traded as low as $1,034 earlier in the session. Investors await commentary at the J.P. Morgan Healthcare Conference and Lilly’s earnings call.
6 January 2026
···
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly shares dropped 3.4% to $1,043.14 after Novo Nordisk launched U.S. sales of an oral Wegovy weight-loss pill starting at $149 a month. Novo’s move intensified focus on pricing in the obesity drug market. The Health Care Select Sector SPDR ETF fell 1.3%, while Novo Nordisk shares rose 2.9%. Investors are awaiting Lilly’s next earnings update on February 4.
5 January 2026
···
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

U.S. drugmakers are raising list prices on at least 350 branded medicines for 2026, with a median increase of about 4%, Reuters reported. The Health Care Select Sector SPDR Fund (XLV) closed up 0.46% at $155.51 Friday. Pfizer, Eli Lilly, and Johnson & Johnson all posted gains. Traders are watching next week’s U.S. jobs data and upcoming healthcare earnings.
3 January 2026
····
Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly shares closed up 0.53% at $1,080.36 Friday, then slipped 0.17% after hours. Drug pricing remains in focus as list-price resets and Medicare negotiations begin the year. Zacks upgraded Lilly to “strong-buy” and Reuters reported a 40% list-price cut for Jardiance. CEO David Ricks will speak at the J.P. Morgan Healthcare Conference on January 13.
3 January 2026
··
Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly shares rose 0.5% to $1,080.36 in after-hours trading Friday after a volatile session. The move follows sector-wide drug price changes and renewed Washington scrutiny, with manufacturers planning 2026 list-price hikes. Investors are watching upcoming U.S. jobs and inflation data, as well as Lilly’s Jan. 13 conference appearance ahead of its Feb. 4 earnings report.
3 January 2026
··
Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, with a median increase of about 4%, according to 3 Axis Advisors. List prices for about nine drugs will drop, including a more than 40% cut for Jardiance after Medicare negotiations. Eli Lilly faces price pressure in both the U.S. and China, where its diabetes drug Mounjaro will also get cheaper from Jan. 1.
1 January 2026
··
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

NEW YORK, December 30, 2025, 5:08 PM ET — After-hours Eli Lilly shares were up 0.1% in after-hours trading on Tuesday at $1,079.75 after a Reuters report said it and Novo Nordisk are lowering prices of their top-selling obesity drugs in China. Reuters The pricing move matters because investors have treated Lilly’s obesity franchise as a main growth engine, helping support a premium valuation. A sharper-than-expected push to discount in large markets can pressure margins, even if it expands the customer base. It also lands as drugmakers pivot toward cash-pay channels — patients paying out of pocket, rather than relying
30 December 2025
···
Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly shares rose 0.2% to $1,078.73 in after-hours trading Monday, with 1.64 million shares traded. Lilly Endowment Inc. disclosed the sale of 2,629 shares at $1,085.17 each, retaining over 92 million shares. Investors focused on obesity drug pricing, with Lilly and Novo Nordisk preparing pill versions and shifting to telehealth and direct-to-consumer sales. The S&P 500 fell 0.35% and the Nasdaq lost 0.5%.
29 December 2025
··
Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly shares closed at $1,077.75, up $0.55, after ABL Bio announced it will receive $40 million upfront and a $15 million equity investment from Lilly under a research deal. The agreement follows a broader pact valued at up to $2.6 billion. Investors are watching for 2026 regulatory decisions on Lilly’s obesity drug pipeline. The S&P 500 and Dow slipped slightly on Friday.
29 December 2025
··
1 … 3 4 5 6 7 8

Stock Market Today

Montage Technology Class A stock slides — traders now fixate on its Hong Kong debut

Montage Technology Class A stock slides — traders now fixate on its Hong Kong debut

8 February 2026
Montage Technology’s Shanghai-listed shares fell 2.74% to 163.54 yuan Friday, extending losses before its Hong Kong debut. The company priced its H-share sale at HK$106.89, raising about HK$6.90 billion. Hong Kong’s public tranche was 707 times subscribed. In grey market trading, shares traded around HK$152.5, 43% above the offer price.
Suzhou TFC Optical (300394.SZ) stock: 3 signals to watch before China’s short, pre-holiday week

Suzhou TFC Optical (300394.SZ) stock: 3 signals to watch before China’s short, pre-holiday week

8 February 2026
Suzhou TFC Optical closed up 0.4% at 252.97 yuan Friday after heavy trading and sharp swings, ranking as the No. 2 most-traded Shenzhen stock via Stock Connect. Margin financing and securities lending fell, with net margin selling of 419 million yuan. Shanghai and Shenzhen markets will close Feb. 16–23 for the Spring Festival. The company expects 2025 net profit to rise 40–60% year-on-year.
Go toTop